Results 31 to 40 of about 920,394 (304)

UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response [PDF]

, 2016
Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide. Despite recent progress, the prognosis of advanced stage CRC remains poor, mainly because of cancer recurrence and metastasis.
Biffoni, Mauro, BUCCARELLI, MARIACHIARA, Cappellari, Marianna, De Luca, Gabriele, Fanciulli, Maurizio, Goeman, Frauke, Melucci, Elisa, PILOZZI, Emanuela, Ricci Vitiani, Lucia, SIGNORE, MICHELE   +9 more
core   +1 more source

Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome. [PDF]

PLoS ONE, 2017
Protein kinases are critical drug targets for treating a large variety of human diseases. Type-III kinase inhibitors have attracted increasing attention as highly selective therapeutics.
Zheng Zhao, Lei Xie, Philip E Bourne
doaj   +1 more source

cAMP-Signalling Regulates Gametocyte-Infected Erythrocyte Deformability Required for Malaria Parasite Transmission. [PDF]

, 2015
Blocking Plasmodium falciparum transmission to mosquitoes has been designated a strategic objective in the global agenda of malaria elimination. Transmission is ensured by gametocyte-infected erythrocytes (GIE) that sequester in the bone marrow and at ...
A Dawn, A Heiber, A Merckx, A Pantaleo, A Sudo, AE Bianco, Audrey Lorthiois, Bernina Naissant, C Lavazec, C Lavazec, C Syin, Catherine Lavazec, CJ Taylor, D Yokoyama, DA Baker, David A. Baker, DK Muhia, Dominique Soldati-Favre, Donatella Taramelli, E Farfour, E Lasonder, E Ling, Eloise Thompson, F Hawking, F Silvestrini, F Silvestrini, Florence Breil, Florian Dupuy, G Deplaine, Ghania Ramdani, Gordon Langsley, HM Taylor, I Koshino, J Bain, K Leykauf, Kenneth Vernick, KM Tang, L Chen, L McRobert, L Wentzinger, LK Read, M Aingaran, M Boolell, M Hliscs, M Tiburcio, M Tiburcio, ME Smalley, MJ Lopez-Barragan, MK Dearnley, MW Dixon, N Goto, N Mohandas, Odile Mercereau-Puijalon, QL Fivelman, R Aguilar, R Joice, RE Sinden, RE Sinden, RL Coppel, Ross Cummings, RW Moon, S D'Alessandro, S Kunz, S Sanyal, SM Knebel, SP Davies, SP Kim, T Bousema, T Harrison, T Ono, T Seebeck, W Trager, WB Smith 2nd, Yoann Duffier, Yolanda Corbett   +74 more
core   +9 more sources

Identification of inactive conformation‐selective interleukin‐2‐inducible T‐cell kinase (ITK) inhibitors based on second‐harmonic generation

FEBS Open Bio, 2018
Many clinically approved protein kinase inhibitors stabilize an inactive conformation of their kinase target. Such inhibitors are generally highly selective compared to active conformation inhibitors, and consequently, general methods to identify ...
Yoshiji Hantani, Kiyosei Iio, Rie Hantani, Kayo Umetani, Toshihiro Sato, Tracy Young, Katelyn Connell, Sam Kintz, Joshua Salafsky   +8 more
doaj   +1 more source

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

BMC Medicine, 2012
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial Parkinson's disease (PD). Variation around the LRRK2 locus also contributes to the risk of sporadic PD.
Rudenko Iakov N, Chia Ruth, Cookson Mark R   +2 more
doaj   +1 more source

Computerized Protein Modeling and Molecular Docking Analysis of Human Proto Oncogene Tyrosine Protein Kinase YES for Discovery of Novel Lead Molecules [PDF]

, 2010
Human proto-oncogene tyrosine-protein kinase YES (YES) is a non receptor kinase belongs to Src family. This gene lies in close proximity to thymidylate synthase gene on chromosome 18, and a corresponding pseudogene has been found on chromosome 22.
Amineni Umamaheswari, Dibyabhaba Pradhan, Karuna J. Jaya Sai   +2 more
core   +2 more sources

Role of mTOR signaling in tumor microenvironment. An overview [PDF]

, 2018
The mammalian target of rapamycin (mTOR) pathway regulates major processes by integrating a variety of exogenous cues, including diverse environmental inputs in the tumor microenvironment (TME).
Bazzichetto, Chiara, Bria, Emilio, Ciuffreda, L., Cognetti, F., COGNETTI, FRANCESCO, Conciatori, Fabiana, Falcone, I., Milella, M., Pilotto, Sara   +8 more
core   +2 more sources

Targeting mTOR for cancer therapy

Journal of Hematology & Oncology, 2019
Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2).
Hui Hua, Qingbin Kong, Hongying Zhang, Jiao Wang, Ting Luo, Yangfu Jiang   +5 more
doaj   +1 more source

Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? [PDF]

, 2011
No abstract ...
Amaravadi, Arunima Mukhopadhyay, Bellodi, Belloni, Boya, Druker, Furst, Gordon, Gozuacik, Gudmundur V Helgason, Jiang, Kalia, Kim, Maria Karvela, Munster, Naka, Ozvegy-Laczka, Savarino, Sharma, Tessa L Holyoake, Zaidi   +20 more
core   +1 more source

Salt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses [PDF]

, 2020
The signalling pathways initiated by members of the transforming growth factor-β (TGFβ) family of cytokines control many metazoan cellular processes, including proliferation and differentiation, epithelial-mesenchymal transition (EMT) and apoptosis. TGFβ
A Rojas-Fernandez, A Woods, AR Ramjaun, AY Hsing, B Bierie, B Ozdamar, B-C Kim, BR Binder, C Allan, CJ David, CS Hill, DB Shackelford, EC Connolly, FA Ran, G Avery-Cooper, G Rena, G Rosti, GD Cuny, GJ Inman, GJ Inman, GM Keating, H Ikushima, J Massagué, J Massagué, J Massaous, J Ozanne, J Song, J Vogt, J Xu, JF Callahan, JL Wrana, JM Lizcano, Joan Massagué, JY Altarejos, K Clark, KA Brown, KJ Livak, LC Spender, LC Spender, M Abe, M Kowanetz, M Tojo, MO Li, MR Keeton, NJ Bright, P Lönn, PH Lin, PK Datta, PM Siegel, RJ Akhurst, RJ Akhurst, S DaCosta Byfield, S Dennler, S Edlund, S Strickson, SA Hawley, T Sonntag, TB Sundberg, Y Drabsch, Y Liu, Y Shi, Y Yang, Y Zhang, Y Zhang   +63 more
core   +2 more sources